[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"palliative-care\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:palliative-care":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,56,0,25,[9,48,84,110,133,164,189,216,239,268,290,317,339,361,390,411,436,467,496,528,552,572,601,627,650],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100249200","phase-1-periganglionic-resiniferatoxin-for-the-treatment-of-intractable-pain-due-to-cancer-induced-bone-pain-100249200",false,"NCT02522611","Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain","An Open-Label, Phase 1b Safety and Efficacy Trial of Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain","-INCLUSION CRITERIA:\n\n1. Male or female subjects must be at least 18 years of age or older.\n2. Must be diagnosed with histologically-confirmed cancer-induced bone pain producing intractable chronic pain in the target area (mid thoracic or chest level down to lower extremities) which was poorly responsive to conservative therapies based on patient report, such as analgesic medication management with potent opioids with or without prior radiotherapy, bisphosphonates, or radioisotope therapy. Additionally, pain that is non-responsive to non-opioid drugs in situations where opioids were not tolerated. Conservative therapies do not include invasive treatments, such as neurolytic procedure, including surgical neurolysis, percutaneous regional or neuraxial continuous infusions (whether opioid or local anesthetic), and peripheral neuromodulation or spinal cord stimulation, but may include temporary diagnostic or therapeutic procedures.\n3. Not currently seeking or receiving potentially curative therapies for cancer (e.g., chemotherapy or immunotherapy). Curative cancer therapy may be sought after the Outpatient Follow Up visit 14 (D14). Palliative anti-tumor therapy is allowed as long as the subject was established on that therapy prior to enrollment.\n4. Must have moderate to severe pain that is not relieved by standard treatments. Mean daily worst pain NRS score of greater than or equal to 6 for pain at or below the T6 dermatome (level of the chest) that is associated with a malignant disease. The mean score must be derived from recordings on at least 4 of 7 consecutive days within 3 weeks preceding treatment.\n5. The subject must agree to undergo a diagnostic periganglionic injection(s) with a long-acting local anesthetic (e.g., bupivacaine) under fluoroscopic guidance which resulted in at least a 30% temporary pain reduction in the targeted pain region lasting for the expected duration of the local anesthetic used.\n6. Must be healthy enough to tolerate study procedures in the judgment of the investigator.\n7. Subjects taking aspirin, non-steroidal anti-inflammatory medications, or vitamin supplements that include vitamin E or any prophylactic anticoagulant (including but not limited to Coumadin, heparin, or Xarelto) will be counseled either to stop taking these at least 7 days before surgery or be given instructions on dosing changes if applicable. In addition, if patients are currently taking a Factor Xa inhibitor (such as Xarelto) a hematology consult will be obtained. Subjects must be willing to comply with this requirement, which is standard clinical practice when undergoing elective surgical procedures to avoid surgical and post-surgical bleeding complications.\n8. Formal review of the subject s medical records and written approval for his\u002Fher inclusion in the study by 3 separate persons:\n\n   * Principal Investigator (PI) or an Associate Investigator (AI).\n   * Medical oncologist or oncologic surgeon.\n   * A member of the Pain and Palliative Care Service (PPCS) at the NIH.\n9. For women of childbearing potential and men with partners of childbearing potential, the ability and willingness use an effective method of contraception during the study.\n\n   Effective methods of birth control include:\n   * hormonal contraception (birth control pills, injected hormones, or vaginal ring).,\n   * intrauterine device.\n   * barrier methods (condom or diaphragm) combined with spermicide\n   * surgical sterilization (hysterectomy, tubal ligation, or vasectomy).\n10. Medical clearance from referring physician consisting of a statement indicating an adequate recovery period from other previous trials\u002Fmedication if known.\n11. Must be able and willing to undergo an eye examination.\n12. Must be able to read, speak and understand English and willing to complete the study tools and forms.\n13. Subjects must have provided written informed consent which includes signing the institutional review board (IRB)-approved consent form prior to participating in any study-related activity.\n14. Must have the capacity to provide informed consent.\n15. Must have a responsible adult to provide assistance with activities of daily living as needed for the subject through the Day 14 visit.\n16. Must have abilityAbility to assign a Durable Power of Attorney (DPA) for research and medical care at NIH.\n\nEXCLUSION CRITERIA:\n\nSubjects will be excluded from the study if they meet any of the following criteria:\n\n1. Subject must not have primary pain source from anatomical regions at T5 dermatome or above.\n2. Subject must not have pain due to causes other than cancer or its treatment that is moderate to severe in intensity.\n3. Subjects must not be undergoing or have plans to undergo any active treatment for their cancer during the study until after the day 14 assessment timepoint, after the RTX injection.\n4. Subject must not be anticipating initiation of palliative anti-tumor therapy or significant changes to current palliative anti-tumor therapy before completion of the Day 14 visit.\n5. Subject must not have an ECG abnormality of which the baseline QTc interval exceeds 450 milliseconds.\n6. Subjects must not have an allergy or hypersensitivity to chili peppers, capsaicin or radiographic contrast agents.\n7. Subject must not have an anatomic abnormality or pathology of the spinal cord and\u002For PG space on magnetic resonance imaging (MRI) that could increase the risk of adverse effects of placement of the needle.\n8. Subject must not have a contraindication to MRI or MRI contrast..\n9. Subjects must not have evidence of a coagulopathy or hemostasis problem as\n\n   evidenced by the following blood laboratory values within the week prior to the planned injection:\n   * PT\u002FINR (prothrombin time\u002FInternational normalized ratio) \\> 1.5 times upper limit of normal range (ULN).\n   * PTT (partial thromboplastin time) \\> 35 seconds.\n10. Subjects must not have a platelet count \\\u003C50,000\u002Fmm3. Platelets will be transfused as necessary to raise the platelet count to greater than or equal to 100,000\u002Fmm3 prior to dosing.\n11. Subjects must not have a total neutrophil count (TNC) \\\u003C1500. The US Clinical Practice Guideline for lumbar puncture is a platelet count of 50,0000, which is higher risk for hemorrhage than periganglionic infection. Patients with TNC\\\u003C1500 (neutropenia) may be eligible later if their TNC level becomes greater than 1500 spontaneously or after use of medications stimulating granulocyte production, such as Neupogen (granulocyte colony stimulating factor: G-CSF).\n12. Subjects must not have abnormal electrolyte levels (i.e. low potassium) that cannot be corrected.\n13. Subjects must not be febrile or have other evidence of an infection within 7 days of the planned periganglionic injection.\n14. Subjects must not have an allergy or hypersensitivity to chili peppers, capsaicin, or radiographic contrast agents.\n15. Female subjects must not be pregnant or breastfeeding.\n16. Subjects with any medical condition that, in the Investigator s opinion, could adversely impact the subject s participation or safety, conduct of the study, or interfere with the pain assessment, such as poorly controlled diabetes or hypertension. Patients can be re-assessed for eligibility if these conditions can be controlled medically.\n17. Subjects may not have a history of heart failure or unexplained fainting (syncope).\n18. Subjects may not have a known family history of long QT syndrome.\n19. Subjects who participated in a clinical trial of an investigational drug or device within 30 days of screening visit or are scheduled to receive an investigational product within 14 days of RTX injection.\n20. Subjects must not have received invasive treatments, such as a neurolytic procedure, including surgical neurolysis, percutaneous regional or neuraxial continuous infusions (whether opioid or local anesthetic), peripheral neuromodulation or spinal cord stimulation.","ALL","18 Years","99 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Background:\n\nCancer-induced bone pain (CIBP) is common in people with cancer. Bone cancer can also lead to anxiety, depression, and reduced mobility and quality of life. Researchers believe a research drug called resiniferatoxin (RTX) may be able to help.\n\nObjective:\n\nTo learn whether RTX is safe and can reduce cancer induced bone pain.\n\nEligibility:\n\nPeople ages 18 and older with CIBP that is not relieved by standard treatments\n\nDesign:\n\nParticipants will have up to 6 outpatient visits over about 7 months. These will include:\n\nMedical history\n\nPhysical exam\n\nBlood and urine tests.\n\nThermal testing: a disk placed on the skin to test ability to sense temperature in and around the area of pain\n\nChest x-ray\n\nEKG: stickers are placed on the chest to measure heart signals\n\nECG: measures electrical activity of the heart\n\nParticipants will have 1 inpatient visit lasting 2-4 days. This will include:\n\nCatheter inserted into a vein in the arm. They are given anesthesia, sedation, and x-ray contrast.\n\nA needle is passed through the skin of the back to inject the RTX.\n\nParticipants will keep a log of the pain medications they take after surgery.\n\nParticipants will be called 1 week and 2, 3, and 4 months after the injection.\n\nParticipants will be mailed surveys and questionnaires to complete 2, 3, and 4 months after the injection.\n\n...",[29,30],"Intractable Pain","Palliative Care",[30,32,33,34],"Adults","Cancer Pain","Quality of Life","NOT_YET_RECRUITING","2026-08-06",{"date":38,"type":39},"2026-08-07","ACTUAL",{"date":41,"type":22},"2026-08-27",{"date":43,"type":22},"2026-12-01",{"name":45,"class":46},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100649602","primary-palliative-care---a-feasibility-cluster-trial-100649602","NCT07737899","Primary Palliative Care - a Feasibility Cluster Trial","PrimPal","Inclusion Criteria:\n\n* Aged 18 years or older.\n* Enrolled as a patient on the list of a recruited General Practitioner in one of the participating Family Health Units.\n* Diagnosed with one or more of the following advanced chronic conditions:\n* Advanced-stage neoplasm (metastatic\u002Fstage IV cancer);\n* Chronic Obstructive Pulmonary Disease (COPD) - GOLD classification III or IV;\n* Congestive Heart Failure (CHF) - New York Heart Association (NYHA) functional classification III or IV;\n* Chronic Kidney Disease (CKD) - stage IV or V.\n\nExclusion Criteria:\n\n* Refusal to provide informed consent or to participate in the study at any point.\n* Disease severity requiring urgent medical intervention (acute crisis\u002Femergency care need at time of recruitment).",{"count":21,"type":22},[57],"NA","This feasibility cluster-controlled randomized trial (RCT) evaluates a complex intervention for the delivery of primary palliative care in Family Health Units (FHUs). The intervention consists of training General Practitioners (GPs) in palliative care through a 30 hour e-learning program and implementing a structured consultation model (4 consultations over 12 weeks) for adult patients with advanced chronic illness. One FHU will receive the intervention and one FHU will follow usual care. The primary goal is to assess feasibility metrics (GP adherence, patient recruitment rate, and patient retention rate), which will inform the design of a subsequent full-scale cluster RCT.",[30,60,61,62,63,64],"Primary Palliative Care","Advanced Cancer","Chronic Obstructive Pulmonary Disease (COPD)","Congestive Heart Failure Chronic","Chronic Kidney Disease (Stages 4 and 5)",[66,60,67,68,69,70,71,72],"Palliative care","General practice","Family medicine","Feasibility study","Cluster randomized controlled trial","Complex intervention","Chronic disease","2026-07-31",{"date":75,"type":39},"2026-08-03",{"date":77,"type":22},"2026-10-01",{"date":79,"type":22},"2027-08-31",{"name":81,"class":82},"University of Coimbra","OTHER",2,{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":17,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":83},"100650131","effectiveness-and-implementation-of-supportive-and-palliative-care-review-kit-in-locations-everywhere-100650131","NCT07745816","Effectiveness and Implementation of 'Supportive and Palliative Care Review Kit in Locations Everywhere'","Effectiveness and Implementation of 'Supportive and Palliative cAre Review Kit in Locations Everywhere' (SPARKLE-2) - A Randomized Controlled Trial","SPARKLE-2","Inclusion Criteria:\n\n* Inclusion criteria for patients:\n\n  1. 21 years old or older\n  2. Diagnosed of advanced cancer diagnosis, defined as metastatic or recurrent\u002F progressive Stage III\u002FIV solid tumour\n  3. Has an unplanned hospital admission and expected to be discharged home\n  4. Able to speak English or Mandarin Chinese or Malay\n  5. Able to provide informed consent\n\n     Additional inclusion criteria for patient participants of semi-structured interviews are:\n  6. Enrolled in the SPARKLE-2 RCT, whether randomized to the SPARKLE intervention or usual care group and regardless of fidelity to trial procedures.\n* Inclusion criteria for caregivers:\n\n  1. 21 years old or older\n  2. Self-endorsing or identified by an enrolled patient as a spouse\u002Fpartner, relative or friend who knows them well and who provides support due to their cancer\n  3. Able to speak English or Mandarin Chinese or Malay\n  4. Able to provide informed consent\n* Inclusion criteria for healthcare providers:\n\n  1. 21 years old or older\n  2. Healthcare professional who is involved in the clinical care of patients with advanced cancer for at least 50% of their work hours\n  3. Able to provide informed consent\n  4. Involved in the processes of the SPARKLE-2\n\nExclusion Criteria:\n\n* Exclusion criteria for patients:\n\n  1. Assessed by the treating physician as unable to complete study procedures\n  2. Unable to complete patient-reported outcome measures\n* Exclusion criteria for caregivers:\n\n  1\\. Unable to complete interviews\n* Exclusion criteria for healthcare providers:\n\n  1. Healthcare professionals that are not providing care for cancer patients.\n  2. Unable to complete interviews","21 Years","120 Years",{"count":95,"type":22},300,[57],"Advanced cancer patients often experience significant physical and emotional symptoms, which can lead to frequent hospital visits and reduced quality of life. Although palliative care can help manage these symptoms and improve well-being, it is often introduced too late.\n\nA proactive symptom monitoring model, SPARKLE-2 aims to identify patients who need palliative care earlier by regularly checking their symptoms using a simple questionnaire. Patients with concerned symptoms will receive timely support from the palliative care team, with the goal of improving their quality of life, reducing unnecessary hospital admissions, and helping more patients receive care in the community rather than in hospital. In the earlier SPARKLE-1 study, it showed the improvement of patients' physical wellbeing. SPARKLE-2 seeks to test the effectiveness among advanced cancer patients with unplanned hospital visits while simultaneously collecting data on real-world implementation.",[99,30],"Neoplasms",[90],"2026-07-30",{"date":103,"type":39},"2026-08-04",{"date":105,"type":22},"2026-08-01",{"date":107,"type":22},"2029-03-31",{"name":109,"class":82},"National Cancer Centre, Singapore",{"id":111,"slug":112,"hasResults":12,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":12,"sex":17,"minAge":92,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":47},"100497250","phase-2-yunzhi-essence-to-improve-the-quality-of-life-of-patients-with-advanced-stage-of-cancer-100497250","NCT05754801","Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer","Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer: A Randomized, Double-blinded, Placebo-controlled Trial","Inclusion Criteria:\n\n* Diagnosed with advanced cancer according to the definition from American Cancer Society;\n* According to the experience of the doctor, by using Palliative Prognostic Index (score\\>4), integrated with past cases and professional knowledge judged to have life expectancy not less than six months to two years;\n* Abbreviated mental test (AMT) score of 6 or above;\n* Voluntarily participate in this clinical trial and sign the informed consent form (acceptance of close relatives signed informed consent on behalf of the patient);\n* Refer to the national standard for Clinic terminology of traditional Chinese medical diagnosis and treatment-Part 2:Syndromes\u002Fpatterns, syndrome of \"damp heat spleen\" and \"spleen deficiency with water stop\" (Fulfill 2 of the main symptoms and 2 of the secondary symptoms).\n\nExclusion Criteria:\n\n* Patients with a history of allergy to traditional Chinese medicine or Yunzhi;\n* Patients who required nasal feeding or difficulty swallowing;\n* Patients with comatose\u002Fsemi-conscious, cognitively impaired with dementia\u002Fconfusion, physically too ill with extremely poor general condition, or there was a language barrier.","89 Years",{"count":119,"type":22},172,[26],"A randomized, double-blinded, placebo-controlled clinical trial using a Chinese Medicine 'Coriolus Versicolor for improving the quality of life of patients with advanced-stage cancer. Subjects will be randomized into a treatment group or placebo group for 6 months.",[123,30],"Cancer","RECRUITING","2026-07-28",{"date":101,"type":39},{"date":128,"type":39},"2024-01-05",{"date":130,"type":22},"2027-09-30",{"name":132,"class":82},"Chinese University of Hong Kong",{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":47},"100643619","nurse-led-caregiver-support-program-in-home-palliative-care-100643619","NCT07593729","Nurse-Led Caregiver Support Program in Home Palliative Care","Effect of a Nurse-Led Caregiver Support Program on Caregiver Competency and Healthcare Utilization Among Family Caregivers in Home Palliative Care: A Randomized Controlled Trial","CARE-PAL","Inclusion Criteria:\n\n* Adult family caregivers of patients receiving home palliative care services\n* Age 18 years or older\n* Being the primary caregiver responsible for the patient's daily care\n* Ability to communicate in Turkish\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* Professional or paid caregivers\n* Caregivers with severe cognitive impairment or severe psychiatric disorders\n* Inability to participate in follow-up assessments",{"count":142,"type":22},150,[57],"This randomized controlled trial aims to evaluate the effect of a nurse-led caregiver support program on caregiver competency and healthcare utilization among family caregivers of patients receiving home palliative care. Family caregivers in the intervention group will receive a structured 6-week nurse-led support program including face-to-face education, weekly telephone coaching, caregiver guidance materials, and decision support for symptom management and healthcare utilization. The control group will continue to receive routine home palliative care services. Primary outcome is caregiver competency. Secondary outcomes include caregiver burden, self-efficacy, patient symptom burden, emergency department visits, and hospitalizations.",[30,146,147],"Caregiver Burden","Home Care",[149,150,151,152,153,66,154],"Nurse-led intervention","Family caregiver","Caregiver competency","Home care","Randomized controlled trial","Healthcare utilization","2026-07-24",{"date":157,"type":39},"2026-07-27",{"date":159,"type":39},"2026-05-12",{"date":161,"type":22},"2026-09-30",{"name":163,"class":82},"Kutahya Health Sciences University",{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":23,"phases":174,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":183,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":47},"100642152","mobile-health-application-for-family-caregivers-in-home-palliative-care-100642152","NCT07654998","Mobile Health Application for Family Caregivers in Home Palliative Care","Effectiveness of a Mobile Health Application for Family Caregivers of Patients Receiving Home Palliative Care: A Randomized Controlled Trial","CARE-Mobile","Inclusion Criteria:\n\n* Family caregiver of a patient receiving home palliative care services.\n* Aged 18 years or older.\n* Providing unpaid care to the patient for at least 3 months.\n* Able to read and understand Turkish.\n* Owns or has regular access to a smartphone compatible with the mobile application.\n* Willing to participate and provide written informed consent.\n\nExclusion Criteria:\n\n* Professional or paid caregivers.\n* Participation in another structured caregiver support program during the study period.\n* Cognitive, visual, or hearing impairments that would prevent effective use of the mobile application.\n* Inability to complete study assessments.\n* Withdrawal of consent at any stage of the study.",{"count":173,"type":22},120,[57],"Family caregivers play a central role in providing daily care for patients receiving home palliative care. However, caregiving responsibilities may lead to increased burden, stress, and difficulties in symptom management and care coordination. Mobile health (mHealth) interventions may provide accessible education, symptom monitoring, and decision-support resources to improve caregiver outcomes and patient care.\n\nThe aim of this randomized controlled trial is to evaluate the effectiveness of a mobile health application developed for family caregivers of patients receiving home palliative care. The primary outcome is caregiver competence. Secondary outcomes include caregiver burden, self-efficacy, patient symptom burden, emergency department visits, and hospitalizations.\n\nA total of 120 family caregivers will be randomly assigned to either the intervention group, which will use the mobile health application for 6 weeks in addition to usual care, or the control group, which will receive usual care alone. Outcomes will be assessed at baseline, post-intervention (Week 6), and follow-up (Week 18).",[30,123,177],"Caregiver",[179,180,181,182,146],"Mobile Health","Family Caregiver","Home Palliative Care","Caregiver Competence",{"date":157,"type":39},{"date":185,"type":39},"2026-06-10",{"date":187,"type":22},"2026-10-30",{"name":163,"class":82},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":215},"100561314","improving-needs-among-older-adults-100561314","NCT06588556","Improving Needs Among Older Adults","Improving Needs Among Older Adults: the ICUconnect 2 Primary Palliative Care RCT","ICUconnect 2","Inclusion Criteria:\n\nPatients (who are not interviewed but whose characteristics prompt enrollment of family members)\n\n1. Adult aged ≥18 years\n2. Managed in an adult medical, cardiac, trauma, surgical, or neurological ICU\n3. Serious acute illness associated with a need for invasive mechanical ventilation\n4. ICU team expect patient to require mechanical ventilation for 2 or more days\n\nFamily members\n\n1. Adult aged ≥18 years\n2. Family member: self-described as the individual (related or unrelated) who provides the most support and with whom the eligible patient has a significant relationship (Society of Critical Care Medicine definition of family; Davidson J, et al. Crit Care Med, 45:103-128; 2017)\n\nICU clinicians\n\n1. Adult aged ≥18 years\n2. ICU clinician: ICU attending caring for the eligible patient on the day of family member informed consent\n\nExclusion Criteria:\n\nPatients\n\n1. Death or full comfort care plan expected within 24 hours by ICU attending or fellow physician Rationale: measurable intervention effect unlikely\n2. Palliative care consultative team and\u002For palliative care specialists are currently involved in the patient's care.\n\n   Rationale: this would dilute the intervention's effect.\n3. ICU length of stay \\>4 days during current ICU admission. Rationale: this would dilute intervention effect by widening the timeframe of family-clinician interactions and limiting standardization.\n\n6\\. Imprisoned person. Rationale: this is a vulnerable population.\n\nFamily members\n\n1. Low palliative care need burden (i.e., NEST scale score \\\u003C15) at baseline. Rationale: if there are very low baseline needs, the intervention cannot impact the primary outcome measure (i.e., NEST).\n2. Lack of English or Spanish fluency, operationalized as need for a translator to understand medical forms or participate in medical discussions.\n\n   Rationale: the app has not been translated into other languages; also, many outcome measures aren't validated in languages other than English and Spanish.\n3. Endorsement of suicidal ideation (i.e., PHQ-9 suicidality item) at the time of baseline data collection.\n\n   Rationale: this indicates a serious level of distress that will require professional assistance beyond that provided by the intervention (or control).\n4. Patient regains decisional capacity after informed consent but before the first family meeting. Rationale: as in our past ICU-based studies, this circumstance (the entry of the patient as a decision maker), would substantially change the nature of the interactions of family members and clinicians.\n5. The ICU clinician changes from a consented clinician to a non-consented clinician before the first family meeting. Rationale: in this circumstance the intervention cannot be fully deployed.\n\nICU clinicians None",{"count":198,"type":22},350,[57],"Millions of older adults receive care in intensive care units (ICUs) annually. However, the quality and accessibility of ICU-based palliative care is highly variable across hospitals and clinicians, due in part to specialists' limited workforce and geographic inconsistency. To address these gaps, the investigators developed an innovative mobile app-based primary palliative care intervention called ICUconnect. ICUconnect facilitates families' and patients' self-report of actual palliative care needs across all core domains of palliative care quality, provides ICU clinicians with a scalable digital infrastructure for coordinating consistent and personalized needs-targeted care, and provides a variety of informational supports relevant to each user's role. In this RCT, the investigators will test ICUconnect vs. usual care control among 350 patient-family member dyads with elevated baseline levels of unmet palliative care need in a 4-site network serving a diverse population (Duke, Medical University of South Carolina, University of Alabama at Birmingham, Columbia).\n\nThe specific aims are to: (1) Test the efficacy of ICUconnect vs. usual care control in improving palliative care needs and other person-centered outcomes including psychological distress, (2) Determine participant characteristics associated with a greater treatment response using a heterogeneity of treatment effects approach, and (3) Ensure off-the-shelf intervention readiness for implementation using a mixed-methods integration of qualitative analysis of semi-structured trial participant interviews and quantitative RE-AIM implementation framework-informed trial data.",[202,30,203,204,205],"Critical Illness","Older Adults","Informal Caregivers","Care Delivery Model","2026-07-22",{"date":208,"type":39},"2026-07-23",{"date":210,"type":39},"2025-09-16",{"date":212,"type":22},"2028-12-31",{"name":214,"class":82},"Duke University",4,{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":223,"targetDuration":4,"studyType":23,"phases":225,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":47},"100118154","phase-1-resiniferatoxin-to-treat-severe-pain-associated-with-advanced-cancer-100118154","NCT00804154","Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer","A Phase I Study of the Intrathecal Administration of Resiniferatoxin for Treating Severe Refractory Pain Associated With Advanced Cancer","* INCLUSION CRITERIA:\n\nSubject inclusion criteria are based on inadequate control of pain despite best efforts, including appropriate use of analgesic medications. To be enrolled in the study, subjects must meet all of the following criteria:\n\n1. Age 18 years or older.\n2. Clinical and histological diagnosis of cancer with disease that has not adequately responded to standard therapies. A pathology report documenting malignancy is required.\n3. Subject not currently seeking or receiving potentially curative therapies for cancer (e.g., chemotherapy or immunotherapy). Curative cancer therapy may be sought after the Day 15 clinic visit, and palliative anti-tumor therapy is allowed as long as the subject was established on that therapy prior to enrollment (see exclusion criterion 6).\n4. Mean daily worst pain NRS score of greater than or equal to 6 for pain at or below the T6 dermatome (level of the chest) that is associated with a malignant disease. The mean score must be derived from recordings on at least 4 of 7 consecutive days within 3 weeks preceding treatment.\n5. Alternative methods of pain control are not sufficiently effective, not indicated, not tolerated, and\u002For refused by the subject, as determined by the Pain and Palliative Care Service (PPCS). Alternative methods of pain control include, but are not limited to, the following:\n\n   -Opioids (all routes of administration including neuraxial infusions)\n\n   -Adjuvant pain medications such as antidepressants, corticosteroids, local anesthetics, and antiseizure medications\n\n   -Procedures such as catheter or implantable pump placement for delivery of analgesic medication\n   * Prior neurolytic interventions (including intercostal, superior hypogastric, or celiac plexus blocks)\n   * Complementary medicine approaches\n   * Transcutaneous electric nerve stimulation\n   * Radiation therapy\n6. Reasonable expectation that the subject will be able to complete the study through the 30-day follow-up.\n7. Medical clearance from referring physician consisting of a statement indicating an adequate recovery period from other previous trials\u002Fmedication.\n8. Formal review of the subject s medical records and written approval for his\u002Fher inclusion in\n\nthe study by 3 separate persons:\n\n* Principal Investigator (PI) or an Associate Investigator (AI)\n* Medical oncologist or oncologic surgeon.\n* A member of the PPCS at the NIH or institution s equivalent at other sites.\n\n  10\\. International normalized ratio (INR; from prothrombin time \\[PT\\]) \\\u003C 1.5 and partial thromboplastin time (PTT) less than or equal to the upper limit of the reference range. The INR and PTT may be corrected (e.g., by administration of blood products, vitamin K, etc.), provided a repeat blood draw confirms that the values meet this inclusion criterion.\n\n  10\\. Platelet count greater than or equal to 50,000\u002Fmm\\^3. Platelets will be transfused as necessary to raise the platelet count to greater than or equal to 100,000\u002Fmm\\^3 prior to dosing.\n\n  11\\. Ability to stop any anticoagulant (e.g., Coumadin) and antiplatelet therapies (e.g., aspirin) before and during IT catheter placement according to accepted medical guidelines.1\n\n  12\\. Ability and willingness to undergo an eye examination.\n\n  13\\. Ability to read, speak, and understand English, and willingness to complete the study tools and forms.\n\n  14\\. For women of childbearing potential and men with partners of childbearing potential, the ability and willingness to use an effective method of contraception during the study. Effective methods of birth control include:\n* hormonal contraception (birth control pills, injected hormones, or vaginal ring),\n* intrauterine device,\n* barrier methods (condom or diaphragm) combined with spermicide, or\n* surgical sterilization (hysterectomy, tubal ligation, or vasectomy).\n\n  15\\. Availability of a responsible adult to assist with activities of daily living as needed for the subject through the Day 15 visit.\n\n  16\\. Ability to assign a Durable Power of Attorney (DPA) for research and medical care at NIH\n\nEXCLUSION CRITERIA:\n\nSubjects will be excluded from the study if they meet any of the following criteria:\n\n1. Primary pain source from anatomical regions at T5 dermatome or above.\n2. Pain due to causes other than cancer or its treatment that is moderate to severe in intensity.\n3. Anatomic abnormality or pathology of the spinal cord and\u002For IT space on magnetic resonance imaging (MRI) that could increase the risk of adverse effects of catheter placement or interfere with CSF flow.\n4. Evidence of advanced brain pathology or elevated intracranial pressure as determined by symptoms, history, physical examination (including neurological and eye examination), and\u002For MRI.\n5. Presence of an IT shunt device (e.g., ventriculo-peritoneal and ventriculo-atrial shunts).\n6. Anticipating initiation of palliative anti-tumor therapy or significant changes to current palliative anti-tumor therapy before completion of the Day 15 visit.\n7. Documented allergy to chili peppers or capsaicin (e.g., hives, wheal).\n8. Contraindication to MRI or MRI contrast.\n9. Female subjects who are pregnant or lactating.\n10. Clinically significant disorder or condition that might interfere with study participation or greatly increase safety risk to the subject, as judged by a study investigator.\n11. Planned use of another investigational agent, therapy, or device within 30 days after dosing.\n12. Have a history of heart failure or unexplained fainting (syncope).\n13. Have an EKG abnormality in which the baseline QTc interval exceeds 450 milliseconds.\n14. Have a known family history of long QT syndrome.\n15. Have abnormal electrolyte levels (i.e., low potassium) that cannot be corrected.\n16. Have urinary retention that does not resolve with medical or surgical treatment.\n17. Have skin ulceration that does not resolve with medical or surgical treatment.\n18. Have a history of seizure activity in the previous month.\n19. Have experienced symptoms of opioid toxicity in the past month (i.e. myoclonus, seizures, and\u002For hallucinations)",{"count":224,"type":22},45,[25],"This study will examine the safety of giving the experimental drug, resiniferatoxin (RTX), to treat severe pain in patients with advanced cancer. RTX is a chemical extracted from a cactus-like plant. It is similar to capsaicin, the active ingredient in hot pepper. RTX has relieved pain and reduced the need for pain medication in several animal experiments. It works by destroying nerves that transmit pain information.\n\nPeople at least 18 years of age with severe pain from advanced cancer at or below the level of the chest that cannot be controlled with standard treatments may be eligible for this study. Participants undergo the following procedures:\n\nPretreatment Visit\n\nBefore beginning treatment with RTX, patients give a medical history and undergo a physical examination that includes:\n\n* Electrocardiogram (EKG)\n* Blood draw\n* Urinalysis\n* Neurological examinations\n* Peak expiratory flow rate (PEFR)\n* Eye examination\n* MRI\n* Urology assessment\n* Pregnancy test, when appropriate\n* Questionnaires to collect information on health, personality, mood, pain levels and symptoms.\n\n  2-Day Hospitalization\n\nPatients are hospitalized for 2 days for RTX injection and monitoring, as follows:\n\n* RTX injection: RTX is injected in the operating room under general anesthesia. It is given through a catheter placed in the patient s spine. The catheter is also used to obtain samples of cerebrospinal fluid (CSF) the clear fluid that bathes the spinal cord. The fluid is examined to assess drug effects and side effects, chemical changes in the content of the CSF associated with RTX, and how RTX is handled by the body.\n* Post-injection monitoring, including:\n* Surveys about symptoms such as pain or weakness\n* Neurological examinations\n* Blood and CSF sampling\n* EKG\n* AEs\n\nOutpatient followup\n\n* Vitals\n* Blood draw, Urinalysis, neurological and sensory testing, EKG on days 7, 14 and 30 after the injection\n* MRI scans of the head and back, Urology assessment and PEFR on day 15 after the injection\n* Eye examination\n* Follow-up phone calls monthly for 6 months",[29,30],[229,230,33,231],"Vanilloid","Capsaicin","Nerve Block",{"date":208,"type":39},{"date":234,"type":39},"2009-08-14",{"date":236,"type":22},"2027-02-07",{"name":238,"class":46},"National Institute of Dental and Craniofacial Research (NIDCR)",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":23,"phases":248,"briefSummary":249,"conditions":250,"keywords":254,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":266,"locationsCount":47},"100598953","the-effect-of-peg-use-education-on-the-care-burden-and-quality-of-life-of-patients-relatives-100598953","NCT07078188","The Effect of PEG Use Education on the Care Burden and Quality of Life of Patients' Relatives","The Effect of Discharge Education on PEG Use Given to Palliative Care Patients' Relatives on the Care Burden and Quality of Life of Patients' Relatives","Inclusion Criteria:\n\n* The caregiver must be over 18 years old\n* The caregiver must be willing and able to participate in the study\n* The caregiver must be primarily responsible for the patient's care\n* The patient they are caring for must be receiving palliative care\n* The patient they are caring for must be receiving PEG feeding\n* The patient they are caring for must be over 18 years old\n* The patient they are caring for must have been diagnosed with stroke at least six months ago\n* The caregiver must have a mini mental test score of 25 points or more\n* The Beck depression scale score must be under 17 points\n* The caregiver must have a score of over 16 points on the Readiness to Provide Care Scale\n\nExclusion Criteria:\n\n* The caregiver is under the age of 18\n* The caregiver is not willing and able to participate in the research\n* The caregiver has a physical disability or serious health problem that makes it difficult to provide care\n* The patient they are caring for is under the age of 18\n* The patient they are caring for has been diagnosed with cancer, endocrine system or GI disease\n* The caregiver has a mini mental test score of less than 25\n* The Beck depression scale score is 17 points or higher\n* The caregiver has scored 16 or lower on the Readiness to Provide Care Scale\n* The caregiver has communication problems\n* The caregiver has been diagnosed with depression or psychiatric disorder\n* The caregiver is receiving psychotherapy\u002Fpsychological support\n* The caregiver is taking antidepressants and\u002For anxiolytics\n* The caregiver has sensory loss related to vision and hearing",{"count":247,"type":22},62,[57],"The study was planned to evaluate the effects of discharge training on PEG use given to palliative care patients' relatives on the caregiver burden and quality of life of the relatives.\n\nThe main questions that the study aims to answer are as follows:\n\n* How does PEG training given before discharge affect the knowledge level of caregivers on PEG use?\n* How does PEG training given before discharge affect the caregiver burden?\n* How does PEG training given before discharge affect the caregiver's caregiver stress?\n* How does PEG training given before discharge affect the quality of life of the caregivers?\n\nThe researchers will compare the PEG training given before discharge with a control group that did not receive training in this regard in order to evaluate the effects of PEG training given before discharge on the caregiver burden, caregiver stress and quality of life of the caregivers. The study will use a general information form, the Caregiver Burden Scale, the Caregiver Stress Index Form, the SF 36 Quality of Life Scale, and the Percutaneous Endoscopic Gastrostomy Tube Nutrition Information Scale for Caregivers.\n\nParticipants:\n\n* Face-to-face interviews will be conducted with caregivers at 0, 1, and 3 months.\n* The forms used in the study will be filled out at each interview.\n* The intervention group will be trained only at the first interview.",[30,177,251,252,253],"Caregiver Burden of Caregivers","Quality of Life of Caregivers","PEG Training",[66,255,256,177,257,258,259],"Nutrition","PEG","caregiver burden","Quality of life","PEG training","2026-07-16",{"date":262,"type":39},"2026-07-20",{"date":264,"type":39},"2023-07-06",{"date":101,"type":22},{"name":267,"class":82},"Uludag University",{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":274,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":276,"targetDuration":4,"studyType":23,"phases":278,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":83},"100587860","promoting-palliative-care-for-people-with-heart-failure-100587860","NCT06933875","Promoting Palliative Care for People With Heart Failure","Promoting Palliative Care for People With Heart Failure: The P3HF Pilot Study","P3HF","Inclusion Criteria:\n\nHealthcare providers must meet the following criteria:\n\n* Are an attending physician, fellow, or resident, advanced practice nurse, or physician associate\n* Has ordering privileges\n* Are members of one of the hospitals' admitting teams (e.g., hospitalist service, cardiology service)\n* Anticipate employment at one of the two study sites for the 15-month trial period.\n\nOr\n\n* Palliative care team member\n* Hospital administrator\u002Fquality and safety personnel\n\nPatients of providers enrolled in the study must meet the following criteria for heart failure during hospitalization:\n\n* Age 18 years of age or older\n* N-terminal pro-B-type natriuretic peptide values of \\>500 pg\u002Fml\n* Received intravenous diuretics within 24 hours of admission.\n\nExclusion Criteria:\n\n* Pregnant at the time of admission.",{"count":277,"type":22},2260,[57],"This project will develop and test a novel clinical decision support tool (CDS) that encourages timely referral to palliative care for people hospitalized with heart failure. This intervention will incorporate an existing, validated 1-year mortality risk model into a CDS to deliver prognostic information and evidence-based decision support at the point of care. Thus, this research may lead to improved care-concordant and goal-directed care for people with heart failure.",[281,30],"Heart Failure","2026-07-14",{"date":260,"type":39},{"date":285,"type":39},"2026-07-02",{"date":287,"type":22},"2027-10-30",{"name":289,"class":82},"Yale University",{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":296,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":23,"phases":299,"briefSummary":300,"conditions":301,"keywords":304,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":313,"leadSponsor":315,"locationsCount":47},"100645426","patient-aid-for-theory-driven-health-communication-path-translating-goal-power-theory-into-an-instrument-and-generative-ai-support-for-palliative-care-communication-100645426","NCT07692711","Patient Aid for Theory-Driven Health Communication (PATH): Translating Goal-Power Theory Into an Instrument and Generative AI Support for Palliative Care Communication","Patients (Self-responding)\n\nInclusion Criteria:\n\n* Age 18 years or older.\n* Diagnosed with an advanced disease requiring consultation with outpatient palliative care clinics or home care services.\n* Able to self-complete the study questionnaires.\n\nExclusion Criteria:\n\n-None\n\nGroup 2: Caregivers (Proxy-responding) (Invited only when the patient meets the clinical criteria but is unable to self-complete the questionnaires)\n\nInclusion Criteria:\n\n* Age 18 years or older.\n* Identified as the primary family caregiver of a patient with an advanced disease requiring palliative care.\n\nExclusion Criteria:\n\n* Professional or paid caregivers.\n* Unable to complete the study questionnaires.",true,{"count":298,"type":22},240,[57],"The goal of this clinical trial is to learn whether an artificial intelligence (AI)-supported communication tool can help improve communication between people receiving palliative care and their healthcare providers. The study will also evaluate a new questionnaire designed to measure the quality of healthcare communication.\n\nThe main questions this study aims to answer are:\n\n1. Can the new questionnaire accurately measure the quality of communication between participants and healthcare providers?\n2. Does using the AI-supported communication tool, called NurseChat+, help participants feel more confident and prepared before meeting with their healthcare team?\n3. Does NurseChat+ improve the quality of communication during palliative care visits?\n\nResearchers will compare participants who use NurseChat+ together with their usual care to participants who receive usual care alone to see whether the tool improves communication outcomes.\n\nThe study will be conducted in three stages. First, researchers will develop and test a questionnaire that measures healthcare communication. Next, they will develop and refine the NurseChat+ tool. Finally, they will test the tool in adults receiving palliative care at National Taiwan University Hospital.\n\nParticipants in the final stage of the study will be randomly assigned to one of two groups. One group will use NurseChat+ before their scheduled medical visits in addition to receiving usual care, while the other group will receive usual care only. Participants will complete questionnaires about their communication experiences during the study.",[30,302,303],"Generative Artificial Intelligence","Natural Language Processing (NLP)",[305,306,307,308,309],"Randomized Controlled Trial","Health Communication","Psychometrics","Theoretical Models","Mixed Methods Research","2026-07-12",{"date":282,"type":39},{"date":105,"type":22},{"date":314,"type":22},"2030-12-31",{"name":316,"class":82},"National Taiwan University Hospital",{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":23,"phases":326,"briefSummary":327,"conditions":328,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":83},"100635457","management-of-dyspnea-with-high--flow-nasal-therapy-100635457","NCT07552935","Management of Dyspnea With High- Flow Nasal Therapy","HFNTpal","Inclusion Criteria:\n\n* The patient is in palliative care (ICD-10 diagnostic code Z51.5 palliative care)\n* Age ≥ 18 years\n* Ability to understand the study and provide informed consent to participate\n* Significant breathlessness (NRS = Numeric Rating Scale ≥ 4).\n* The treating physician has assessed that the patient would not benefit from treatment in intensive care unit or monitor unit.\n* The treating physician has assessed that the patient would not benefit from invasive mechanical ventilation (intubation) or cardiopulmonary resuscitation.\n\nExclusion Criteria:\n\n* Decreased level of consciousness, delirium, or other lack of cooperation that prevents participation.\n* Respiratory support other than HFNT is required.\n* The patient has received HFNT during the same admission to palliative care ward or hospice.\n* The cause of dyspnea can be treated immediately.\n* Inability to provide informed consent to participate.",{"count":325,"type":22},40,[57],"Dyspnea in patients with incurable illness is a difficult symptom. Therefore, there is a need to identify new effective treatment modalities. Previous studies suggest that high-flow nasal therapy delivered via a nasal cannula (HFNT = High-Flow Nasal Therapy) may alleviate dyspnea, and similarly that directing airflow toward the face can provide relief. HFNT has been studied very little in hospice settings and on palliative care wards. The aim of this study is to determine whether HFNT is a feasible and effective treatment for relieving dyspnea in patients receiving palliative care.\n\nPatients will be recruited from the Hatanpää Palliative Care Ward and the Pirkanmaa Hospice, Tampere, Finland. The target is to recruit approximately 30-40 patients. The inclusion criteria are: age ≥18 years, ability to understand the study and provide informed consent to participate, a palliative treatment approach, and significant dyspnea.\n\nEach patient receives HFNT and fan therapy in which airflow will be directed toward the patient's face. Both treatments will last 30 minutes. Patient symptoms will be asked after the treatments. In addition, patients will be asked to rate the overall benefit they experienced from the intervention and any side effects. The primary endpoint is the relief of dyspnea with HFNT compared with fan therapy.\n\nThe study will be conducted in accordance with laws, regulations, and guidelines governing medical research, as well as good scientific practice and research ethics. The study does not involve significant risks or measurements or sampling procedures that would cause additional discomfort. All other care for the patient will be provided according to the standard practices of the treating unit, and participation in the study will not limit any necessary treatments. Identifiable information will not be disclosed for use outside the research group. Results will be reported in a manner that does not allow patients to be identified. The Ethics Committee of the Wellbeing Services County of Pirkanmaa has approved the study.\n\nIf successful, the study will significantly improve the care of the patients in palliative care.",[30,329],"Breathlessness","2026-06-25",{"date":332,"type":39},"2026-06-30",{"date":334,"type":39},"2026-06-01",{"date":336,"type":22},"2029-12-31",{"name":338,"class":82},"Tampere University Hospital",{"id":340,"slug":341,"hasResults":12,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":23,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":47},"100644990","oncologic-timely-palliative-care-and-remote-monitoring-with-electronic-assessments-and-telehealth-on-target-100644990","NCT07674797","Oncologic Timely Palliative Care And Remote Monitoring With Electronic Assessments And Telehealth (ON-TARGET)","Eligibility Criteria\n\n* Age ≥ 18\n* Outpatients who are within 12 weeks of diagnosis of metastatic solid tumors and seen by one of the participating medical oncologists\n* Eastern Cooperative Oncology Group Performance Status 0.2\n* Able to speak English or Spanish\n\nExclusion Criteria:\n\n. Cognitive impairment in the opinion of the oncologist necessitating need for a surrogate decision making.\n\n• Previously seen by SPC team at UT MD Anderson",{"count":95,"type":22},[57],"To examine how we can provide supportive care for patients with advanced cancer better tailored to their needs",[349,30,350,351,352],"Oncologic","Remote Monitoring","Electronic Assessments","Telehealth","2026-06-24",{"date":332,"type":39},{"date":356,"type":22},"2026-11-22",{"date":358,"type":22},"2034-06-30",{"name":360,"class":82},"M.D. Anderson Cancer Center",{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":375,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":215},"100637389","the-effect-of-progressive-muscle-relaxation-and-deep-breathing-exercises-applied-to-palliative-care-cancer-patients-on-dyspnea-fatigue-and-self-care-behaviors-100637389","NCT07619209","The Effect of Progressive Muscle Relaxation and Deep Breathing Exercises Applied to Palliative Care Cancer Patients on Dyspnea, Fatigue, and Self-Care Behaviors","Inclusion Criteria:\n\n* Being 18 years of age or older\n\nBeing literate (able to read and write)\n\nHaving no significant hearing or visual impairment that prevents communication or cooperation\n\nReceiving treatment in the palliative care unit\n\nHaving a confirmed medical diagnosis of cancer\n\nHaving a Glasgow Coma Scale (GCS) score of 10 or higher\n\nBeing able to communicate via telephone and SMS for post-discharge follow-up\n\nHaving a Common Terminology Criteria for Adverse Events (CTCAE) Dyspnea Classification of Grade 3 or below\n\nHaving an ECOG Performance Status Scale score of 3 or below\n\nHaving a Hemoglobin (Hb) value of 8 gm\u002FdL or higher\n\nVolunteering to participate in the study and providing informed consent\n\nExclusion Criteria:\n\n* Currently practicing or having recently practiced Progressive Muscle Relaxation (PMR) or deep breathing exercises actively\n\nHaving a primary respiratory system disease diagnosis (such as COPD, asthma, or pneumonia)\n\nHaving a medical diagnosis of dementia, agitation, or delirium\n\nReceiving Continuous Positive Airway Pressure (CPAP) or Bilevel Positive Airway Pressure (BiPAP) support\n\nBeing on active antipsychotic or sedative medical treatment\n\nHaving a Common Terminology Criteria for Adverse Events (CTCAE) Dyspnea Classification of Grade 4 or higher",{"count":368,"type":22},90,[57],"The purpose of this study is to evaluate the effects of Progressive Muscle Relaxation (PMR) exercises and deep breathing exercises on dyspnea, fatigue, and self-care behaviors among cancer patients receiving palliative care. Advanced-stage cancer patients frequently experience debilitating symptoms such as shortness of breath (dyspnea) and severe fatigue, which significantly impair their functional capacity and daily self-care activities. Participants in this study will be assigned to either a progressive muscle relaxation intervention group or a structured deep breathing exercise group. The study aims to determine whether these non-pharmacological relaxation techniques can effectively reduce the severity of dyspnea and fatigue, thereby improving the patients' overall self-care behaviors and physical comfort in a palliative care setting.",[123,372,30,373,374],"Fatigue","Progressive Muscle Relaxation","Patient",[30,376,373,377,378,379,380,305],"Cancer Patients","Deep Breathing Exercises","Dyspnea Management","Cancer-Related Fatigue","Self-Care Behaviors","2026-05-30",{"date":383,"type":39},"2026-06-03",{"date":385,"type":39},"2026-01-01",{"date":387,"type":22},"2026-12",{"name":389,"class":82},"Ankara University",{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":23,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":4},"100640213","effectiveness-and-implementation-of-the-dinknesh-digital-palliative-care-tool-in-ethiopia-100640213","NCT07574281","Effectiveness and Implementation of the DINKNESH Digital Palliative Care Tool in Ethiopia","Effectiveness and Implementation Determinants of the DINKNESH App Compared to Paper-Based Assessment Tools for Palliative Care: A Mixed-Methods Cluster Randomized Trial in Addis Ababa, Ethiopia","Inclusion Criteria\n\n* For patients(Quantitative Part):\n\n  * Adults aged 18 years or older\n  * Currently diagnosed with one or more chronic conditions and receiving home-based follow-up care from a participating Family Health Team within the catchment area of a selected study cluster\n  * Willing to provide verbal informed consent, or has a primary caregiver willing to provide proxy consent\n* For healthcare workers:\n\n  * Staff members of the Family Health Team at the selected clusters\n  * Involved in delivering or supervising palliative care services during the study period\n  * For the qualitative part: Participated in the DINKNESH App implementation process and is willing to participate in a Focus Group Discussion (FGD)\n\nExclusion Criteria\n\n* For patients\n\n  * Patients whose clinical condition prevents both self-participation and proxy participation in the assessment process\n  * Patients already formally identified and referred for palliative care prior to the study period\n* For healthcare workers:\n\n  * Staff members planning to be absent for more than 1 day during the six-week active study period\n  * Healthworkers not present during the training session",{"count":398,"type":22},1440,[57],"The goal of this clinical trial is to learn if a digital health app called DINKNESH is effective for palliative care identification compared to traditional paper-based assessment tools. It will also look at the factors that help or hinder the use of this app in primary care settings.\n\nThe main questions it aims to answer are:\n\nDoes the DINKNESH app improve palliative care assessments compared to paper forms?\n\nWhat are the main barriers and facilitators for Health Extension Workers when using the app in their daily work?\n\nWe will compare the DINKNESH app to standard paper-based tools to see if digital tools improve clinical assessment and implementation.\n\nParticipants will:\n\nBe assessed for palliative care needs using either the DINKNESH mobile app or standard paper forms.\n\nReceive routine follow-up care as determined by their health provider.\n\n(For health workers): Participate in interviews or surveys to discuss their experience using the assigned assessment tool.",[30],"2026-05-04",{"date":404,"type":39},"2026-05-07",{"date":406,"type":22},"2026-04",{"date":408,"type":22},"2026-05",{"name":410,"class":82},"Addis Ababa University",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":23,"phases":421,"briefSummary":422,"conditions":423,"keywords":426,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":4},"100636569","virtual-reality-therapy-for-improving-caregiver-and-patient-quality-of-life-in-home-based-palliative-care-in-saudi-arabia-100636569","NCT07567391","Virtual Reality Therapy for Improving Caregiver and Patient Quality of Life in Home-Based Palliative Care in Saudi Arabia","Virtual Reality Nature Therapy for Palliative Patients and Caregivers in Saudi Arabia: A Randomized Controlled Trial to Support Quality of Life and Cultural Adaptation","VIRTIC-Hajj","Inclusion Criteria:\n\n* Adult patients (≥18 years) receiving palliative care in Saudi Arabia\n* Primary family caregivers living with and providing daily care to the patient\n* Ability to provide informed consent\n* Fluent in Arabic\n\nExclusion Criteria\n\n* Severe cognitive impairment or psychiatric conditions that prevent use of VR\n* History of epilepsy or vestibular disorders\n* Inability to understand or follow instructions for using VR equipment",{"count":420,"type":22},100,[57],"This randomized controlled trial evaluates the efficacy of a culturally adapted virtual reality (VR) nature therapy intervention aimed at improving the quality of life (QOL) and emotional well-being of palliative patients and their family caregivers in Saudi Arabia. The study involves immersive VR sessions depicting natural environments, including Saudi-specific landscapes, delivered to patient-caregiver dyads at home. Outcomes include self-reported QOL measures, psychophysiological parameters, and qualitative feedback.",[424,34,30,425],"Virtual Reality","Caregivers",[424,30,34,425],"2026-05-03",{"date":429,"type":39},"2026-05-05",{"date":431,"type":22},"2026-10-20",{"date":433,"type":22},"2027-09-01",{"name":435,"class":82},"University of Bisha",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":296,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":23,"phases":446,"briefSummary":447,"conditions":448,"keywords":451,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":47},"100612017","effectiveness-of-the-mindful-compassion-care-program-for-healthcare-professionals-in-oncology-and-palliative-care-100612017","NCT07248111","Effectiveness of the Mindful Compassion Care Program for Healthcare Professionals in Oncology and Palliative Care","Effectiveness of the Mindful Compassion Care Program for Healthcare Professionals in Oncology and Palliative Care: a Randomized Controlled Trial With a Qualitative Component","MCCP","Inclusion Criteria:\n\n* Being a healthcare professional (physicians, nurses, or nursing assistants) involved in the clinical management of cancer patients across different care settings and illness phases.\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* HPs must not have attended MBSR or other mindfulness\u002Fcompassion-based interventions, including in educational or clinical settings, involving activities similar to those in the present study in the previous six months.",{"count":445,"type":22},160,[57],"This randomized controlled trial aims to evaluate the effectiveness of the Mindful Compassion Care Program (MCCP), a mindfulness- and compassion-based intervention designed to enhance the emotional and professional well-being of healthcare professionals (HPs). The study adopts a multi-center, open-label, randomized, parallel-group, superiority design and includes HPs (physicians, nurses, and nursing assistants) involved in the clinical care of cancer patients across different settings and disease phases. Eligible participants must not have attended MBSR or other mindfulness-\u002Fcompassion-based interventions in the preceding six months.\n\nThe RCT has a primary objective of assessing the MCCP's effectiveness in increasing positive emotions and reducing negative emotions among HPs working in oncology and palliative care. Secondary objectives include evaluating improvements in professional quality of life and self-compassion. After providing informed consent, HPs will be randomized to receive either the MCCP (experimental group) or no intervention (control group).",[449,30,450],"Professional Quality of Life","Oncology",[452,453,454,455,456],"mindfulness","self-compassion","emotional regulation","supportive care","mental health promotion","2026-04-28",{"date":459,"type":39},"2026-04-29",{"date":461,"type":22},"2027-12",{"date":463,"type":22},"2028-01",{"name":465,"class":466},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":473,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":17,"minAge":475,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":23,"phases":478,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":215},"100507142","phase-2-lysergic-acid-diethylamide-lsd-in-palliative-care-100507142","NCT05883540","Lysergic Acid Diethylamide (LSD) in Palliative Care","Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)","LPC","Inclusion Criteria:\n\n* Age ≥ 22 years.\n* Advanced or End-stage fatal disease of any cause with a life expectancy ≥ 12 weeks and ≤ 2 years\n* Sufficient understanding of the study procedures and risks associated with the study.\n* Participants must be willing to adhere to the study procedures and sign the consent form.\n* Participants must be willing not to drive a traffic vehicle or to operate machines within 24 h after LSD administration.\n* Participants must complete an actual \"Emergency Medical Directive\"\n* Participants with central nervous system (CNS) involvement of cancer are eligible if the following apply:\n\n  * treated and stable CNS lesion(s) OR untreated but asymptomatic\u002Fstable lesions, defined as clinically and\u002For radiologically stable for ≥ 4 weeks before screening\n  * no seizures within ≥ 4 weeks; if on antiepileptic medication: stable dose ≥ 4 weeks and no relevant drug-drug interactions expected\n  * no requirement for high-dose corticosteroids, defined as ≤10 mg prednisone equivalent per day on a stable or decreasing dose\n  * no leptomeningeal metastases\n  * no concomitant therapeutic anticoagulation\n\nExclusion Criteria:\n\n* Life expectancy \\< 12 weeks\n* Known hypersensitivity to LSD\n* Requiring ongoing concomitant therapy with a psychoactive prescription drug which might interfere with the study drug, and unable or unwilling to comply with the washout period.\n* Current use of a potent drug CYP2D6 inhibitor\n* Women who are pregnant or nursing or intend to become pregnant during the course of the study.\n* Somatic disorders including CNS involvement of cancer, untreated epilepsy with a history of generalized grand-mal seizures, history of delirium, end-stage heart failure (NYHA IV), untreated hypertension or insufficiently treated hypertension, angina pectoris, severe liver disease or severely impaired renal function, or other that in the judgement of the investigators pose too great potential for side effects.\n* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant.\n* Participation in another study with an investigational drug within the 30 days preceding and during the present study\n* concomitant diagnosis of past or present psychotic disorder, first-degree relative with psychotic disorders\n* concomitant diagnosis of past or present bipolar disorder\n* current delirium\n* substance use disorder (within the last 2 months, except nicotine, opioids used for analgesia, and benzodiazepine treatment for anxiety).\n* Weight \\< 45 kg\n* Suicidal ideation with active intent or plan to act on suicidal thoughts as assessed by the treating investigator.\n* CNS involvement of cancer if\n\n  * CNS disease is unstable or high-risk, including clinically and\u002For radiologically progressive lesions, signs of raised intracranial pressure, radiologically uncontrolled edema, need for escalating corticosteroid doses, or any neurological condition judged to pose too excessive risk.\n  * CNS-directed therapy (surgery and\u002For radiation) within ≤ 4 weeks","22 Years",{"count":477,"type":22},60,[26],"Background: Terminally ill patients often experience significant psychosocial distress having depressed mood, death anxiety, pain, and an overall poor quality of life. Recent evidence from pilot studies suggests that serotonergic hallucinogens including lysergic acid diethylamide (LSD) and psilocybin produce significant and sustained reductions of depressive symptoms and anxiety, along with increases in quality of life, and life meaning in patients suffering from life-threatening diseases. Additionally, serotonergic hallucinogens may produce antinociceptive effects.\n\nObjective and Design: The study aims to evaluate effects of LSD on psychosocial distress in 60 patients suffering from an advanced or end-stage fatal disease with a life expectancy ≥12wks and ≤2yrs in an active placebo-controlled double-blind parallel study. Patients will be allocated in a 2:1 ratio to one of the two intervention arms receiving either two moderate to high doses of LSD (100 µg and 100 µg or 100 µg and 200 µg) as intervention and two low doses of LSD (25 µg and 25 µg) as active-placebo control.",[30,481,482,483,484,485,34,146,486,487],"Pain","Anxiety","Depression","Demoralization","Psychological Distress","Fear of Death","Existential Distress","2026-04-23",{"date":459,"type":39},{"date":491,"type":39},"2024-06-09",{"date":493,"type":22},"2028-05",{"name":495,"class":82},"University Hospital, Basel, Switzerland",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":23,"phases":505,"briefSummary":506,"conditions":507,"keywords":511,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":47},"100634918","single-arm-monocentric-pilot-feasibility-study-on-an-interactive-virtual-reality-program-in-20-complex-in-clinic-palliative-care-patients-100634918","NCT07545928","Single Arm, Monocentric, Pilot Feasibility Study on an Interactive Virtual Reality Program in 20 Complex In-clinic Palliative Care Patients","ZENCTUARY_VR+","Inclusion Criteria:\n\n* Patient ≥ 18 years old, hospitalized at the USP - HUS\n* Estimated life expectancy ≥ 1 month (Pronopall score based on clinical data).\n* Montreal Cognitive Assessment (MoCA) scale score ≥ 26.\n* Able to understand the objective and risks of the study\n* VRISE score ≤ 25 after the VR familiarization procedure\n* Affiliation with the Social Security system or beneficiary of such social protection.\n* Signed consent from, able to understand and complete the questionnaires in French.\n\nExclusion Criteria:\n\n* Patients with psychiatric disease\n* Patients under court protection\n* Uncontrolled epilepsy\n* Visual impairments (lack of binocular vision, blindness) and\u002For hearing impairments (deafness) preventing the use of virtual reality",{"count":504,"type":22},20,[57],"Palliative care patients frequently face a \"symptom cluster\" of pain (up to 96%), fatigue (up to 90%), and anxiety (up to 79%), which severely degrades their quality of life in their final months.The study is built on the concept of passive exposure therapy (VREP), which engages multiple senses to distract the brain from pain signals. By creating an \"immersive distraction\" or a \"flow state,\" VR can activate the brain's reward networks and reduce activity in areas associated with pain perception. Unlike most existing VR research in palliative care which uses \"passive\" VR (like watching a 360-degree video), this study uses interactive VR. Patients can perform simple actions-like grabbing or dropping virtual objects-within a calming natural environment, which may better support their sense of autonomy and dignity. Because this is a pilot study, the \"Go\u002FNo-Go\" decision for future larger trials depends on a strict composite of three factors:\n\n* Adherence: The patient must complete at least 11 out of 14 planned daily sessions.\n* Duration: Each session must average at least 7.5 minutes of usable VR exposure.\n* Tolerance: The patient must experience no device-related serious adverse events and maintain a high average tolerance score (VRISE score ≥ 25).",[30,508,482,509,510,485],"Refractory Pain","Depression Disorders","Fatigue, Mental",[512,513,514,515,516,517,518],"palliative care","end-of-life care","refractory pain","Interactive Virtual Reality","Immersive Technology","Virtual Reality Exposure Therapy (VRET)","Cybersickness in Palliative Care","2026-04-15",{"date":521,"type":39},"2026-04-22",{"date":523,"type":22},"2026-09-01",{"date":525,"type":22},"2027-03-01",{"name":527,"class":82},"University Hospital, Strasbourg, France",{"id":529,"slug":530,"hasResults":12,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":534,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":537,"phases":4,"briefSummary":538,"conditions":539,"keywords":541,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":47},"100630766","palliative-and-supportive-care-to-help-people-with-arthritis-to-live-well-enrich-100630766","NCT07491939","Palliative and Supportive Care to Help People With Arthritis to Live Well (ENRICH)","Exploring Perspectives on Palliative and Supportive Care, to Inform Recommendations to Help People Live Well With Inflammatory Arthritis Throughout the Disease Course (ENRICH)","ENRICH","Inclusion Criteria:\n\n* Adults (\\> 18 years) with a diagnosis of arthritis (Rheumatoid, Psoriatic or Juvenile Idiopathic) or Axial Spondyloarthritis\n* able to understand and communicate in verbal and written English (or via an interpreter nominated by the participant or provided via an agency by the research team)\n* in receipt, or not in receipt of Palliative Care services\n* access to Microsoft Teams or a telephone\n* consent to sharing preferred contact details\n\nExclusion Criteria:\n\n* Cognitive impairment that impedes communication\n* non-English speaker (should an interpreter not be available).",{"count":173,"type":22},"OBSERVATIONAL","Palliative Care (PC) focuses on maximising quality of life and care for patients and their families in the last 1000 days of life. Supportive Care (SC) is provided earlier in life for people with a long-term health condition.\n\nPeople living with inflammatory arthritis, (such as rheumatoid arthritis) can experience ongoing pain, stiffness, limitations in their joints, and intrusive fatigue. This impacts daily living activities and emotional well-being. People with inflammatory arthritis would value support to manage symptoms across the course of their disease. They would like PC healthcare professionals (HCPs) to understand their conditions better, so they can live well to the end of their lives.\n\nAims:\n\nThe investigators will explore the potential role of Palliative and Supportive Care (PSC) for people with inflammatory arthritis. The investigators will describe any unmet patient need. The investigators will develop clinical and research recommendations to help people with inflammatory arthritis live well over the course of their disease.\n\nPlan:\n\nThe investigators research will be conducted in three studies:\n\nStudy 1: The investigators will conduct 1:1 online interviews with people with inflammatory arthritis to understand how PSC is perceived by them, and what their views are on how PSC may support them to live well.\n\nStudy 2: The investigators will send an online survey to Rheumatologists, Primary Care, Community and PC HCPs, to understand:\n\n* if and how they work together currently;\n* their views on the role of PSC supporting people with inflammatory arthritis to live well.\n\nStudy 3: The investigators will conduct online focus groups with volunteers from Studies 1 and 2, representatives from relevant national charities\u002Forganisations, and people who commission health services. Together the group will discuss the research findings and agree:\n\n* what the gap in patient care is;\n* recommendations for future clinical practice and research;\n* the key areas of importance for patients which should be measured in future work",[540,30],"Inflammatory Arthritis",[542,30],"Inflammatory arthritis","2026-03-24",{"date":545,"type":39},"2026-03-25",{"date":547,"type":39},"2026-02-19",{"date":549,"type":22},"2027-04",{"name":551,"class":82},"Dorothy House Hospice",{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":556,"acronym":557,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":537,"phases":4,"briefSummary":560,"conditions":561,"keywords":562,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":569,"leadSponsor":570,"locationsCount":47},"100630321","complex-decisions-regarding-antithrombotic-therapy-the-quiet-study-100630321","NCT07486154","Complex Decisions Regarding Antithrombotic Therapy: the QUIET Study","QUIET","Inclusion Criteria:\n\n* Affiliation, as a physician, with one of the main Italian scientific societies actively involved in the management of antithrombotic therapy in patients referred to Palliative Care\n* Electronic informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Failure to complete or incomplete completion of the questionnaire.",{"count":95,"type":22},"\"Complex decisions regarding antithrombotic therapy: the QUIET study\" is a monocentric observational study without drug intervention, conducted through the administration of a questionnaire (survey).The aim of this study is to explore, through the administration of a questionnaire (survey) consisting of hypothetical clinical cases, the approach of physicians regarding the prescription, continuation, or discontinuation of antithrombotic therapies in patients referred to Palliative Care.",[30],[563,564,512],"antithrombotic therapy","end of life","2026-03-17",{"date":567,"type":39},"2026-03-20",{"date":406,"type":22},{"date":549,"type":22},{"name":571,"class":82},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":579,"targetDuration":4,"studyType":23,"phases":580,"briefSummary":581,"conditions":582,"keywords":588,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":592,"lastUpdatePostDateStruct":593,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":47},"100629062","multidisciplinary-care-pathway-tailored-on-frailty-in-cancer-patients-referred-to-outpatient-palliative-care-100629062","NCT07469761","MultidISciplinary Care paThway tailoRed on frAilty in Cancer Patients Referred to Outpatient paLliative Care","MISTRAL","Inclusion Criteria:\n\n* diagnosis of advanced\u002Fmetastatic cancer\n* age \\> 18\n* Eastern Cooperative Oncology Group (ECOG) performance status ≥2\n* prognostic clinical prediction \\>1 month.\n\nExclusion Criteria:\n\n* Serious medical or psychiatric illness that can interfere with informed consent and participation in this clinical study\n* any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.",{"count":173,"type":22},[57],"The goal of this clinical trial is to learn whether a structured, Patient-Reported Outcome Measures (PROMs)-tailored palliative care pathway improves clinical outcomes and care experience in adults with advanced cancer referred to outpatient palliative care.\n\nPatients with advanced cancer often experience multiple symptoms and complex needs. Standard outpatient palliative care is usually guided by clinical judgment on patient-reported questionnaires. In this study, researchers aim to test whether a more structured approach, based on predefined cut-offs from PROMs, can improve symptom control, satisfaction with care, and use of healthcare resources. The main questions the study aims to answer are:\n\nDoes a structured, PROM-driven palliative care pathway reduce symptom burden and psychological distress compared with usual care? And through this, to improve patients' and caregivers' satisfaction with care or reduce emergency room visits, hospital admissions, healthcare costs, and aggressive treatments near the end of life?\n\nResearchers will compare two groups:\n\nControl group: Participants will receive standard outpatient palliative care. PROMs are collected as usual, but without predefined cut-offs or structured intervention checklists.\n\nExperimental group: Participants will receive a structured palliative care pathway tailored to symptoms\u002Fneeds identified at baseline using PROM cut-offs. Specific multidisciplinary interventions are activated according to identified needs.",[30,583,584,585,586,123,587],"Palliative Care, Health Services","Patient Reported Outcome (PRO)","Patient Reported Outcome Measurements","Frailty","Outpatient",[589,587,30,590,586,591],"Patient Reported Outcome Measurements (PROMs)","Advanced cancer","Palliative Care intervention","2026-03-09",{"date":594,"type":39},"2026-03-13",{"date":596,"type":39},"2025-11-02",{"date":598,"type":22},"2027-02-28",{"name":600,"class":82},"Augusto Caraceni",{"id":602,"slug":603,"hasResults":12,"nctId":604,"briefTitle":605,"officialTitle":606,"acronym":607,"eligibilityCriteria":608,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":609,"targetDuration":4,"studyType":23,"phases":610,"briefSummary":611,"conditions":612,"keywords":616,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":625,"locationsCount":83},"100627230","palliative-care-intervention-to-improve-health-related-quality-of-life-for-patients-on-long-term-lvad-support-100627230","NCT07445932","Palliative Care Intervention to Improve Health Related Quality of Life for Patients on Long-Term LVAD Support","The PALL-VAD Study: Palliative Care Intervention to Improve Health Related Quality of Life for Patients With Heart Failure on Long-Term LVAD Support: A Pilot, Prospective, Randomized Trial","PALL-VAD","Inclusion Criteria:\n\n* LVAD patients \\>= 18 years of age\n* \\>= 1 year post-LVAD implantation\n\nExclusion Criteria:\n\n* Listed for heart transplantation. Undergoing evaluation for heart transplantation, however, is not an exclusion.\n* Non-English speaking\n* Receiving outpatient palliative care in the last 6 months\n* Renal replacement therapy\n* Non-cardiac terminal illness\n* Women who are pregnant or planning to become pregnant\n* Inability to comply with study protocol and follow up\n* Inabilty to provide consent.\n* Cognitive impairment or intellectual disability that prohibits successful completion of the HRQoL scales or compliance with the study protocol and follow up.",{"count":368,"type":22},[57],"Background: While left ventricular assist device (LVAD) therapy improves survival in patients with advanced heart failure (AHF), unique LVAD-related burdens may impact health-related quality of life (HRQoL). Palliative care specialists are key members of the multidisciplinary care team for patients with long-term-LVAD (LT-LVAD), offering specialized, comprehensive, holistic care.\n\nProblem: A seminal study of palliative care in patients with heart failure (PAL-HF trial) demonstrated that outpatient palliative care improved HRQoL, depression, anxiety, and spiritual well-being compared to usual care. The impact of longitudinal palliative care on HRQoL in LT-LVAD patients is unknown.\n\nObjective: The investigators aim to conduct the first study examining a palliative care intervention to improve HRQoL among LT- LVAD recipients (patients who have lived with LT-LVAD for at least six months and are not heart transplant candidates) at two centers (MedStar Health and Inova) in the Mid-Atlantic Region. Given the demographics of the study institutions, the investigators anticipate a socioeconomically and racially diverse cohort of patients with subgroups who may disproportionately experience LVAD-related burdens relative to benefits.\n\nAims: The first aim is to assess baseline measures of HRQoL in LT-LVAD patients to understand differences in HRQoL across subgroups and multiple, understudied domains. The second aim is to test the feasibility and acceptability of a randomized, unblinded pilot study of a palliative care interdisciplinary intervention in this population.\n\nSignificance: Results of this study will inform the development of a large randomized controlled trial to test the effectiveness of palliative care intervention in improving HRQoL in LT-LVAD patients. If results are positive, this will revolutionize the post-LVAD treatment paradigm, by making palliative care integration the standard of care for longitudinal LT-LVAD patient management.",[613,614,615,30],"Advanced Heart Failure","Mechanical Circulatory Support","Left Ventricular Assist Device",[617,618,512],"advanced heart failure","left ventricular assist device","2026-02-25",{"date":621,"type":39},"2026-03-03",{"date":623,"type":22},"2026-03-01",{"date":525,"type":22},{"name":626,"class":82},"Medstar Health Research Institute",{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":296,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":635,"targetDuration":4,"studyType":537,"phases":4,"briefSummary":637,"conditions":638,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":642,"lastUpdatePostDateStruct":643,"startDateStruct":645,"completionDateStruct":646,"leadSponsor":648,"locationsCount":47},"100617892","oral-health-in-palliative-care-a-survey-study-100617892","NCT07324525","Oral Health in Palliative Care: A Survey Study","Oral Health and Dental Care in Palliative Medicine: A Survey Study Among Patients and Members of the German Society for Palliative Medicine","OH-PAL","Inclusion Criteria:\n\n* consent-capable patients receiving palliative care\n* patients whose health status allows completion of a questionnaire\n* consent-capable members of the German Society for Palliative Medicine\n\nExclusion Criteria:\n\n* Participants under 18 years of age\n* Individuals who are unable or unwilling to provide informed consent",{"count":636,"type":22},151,"Oral health problems such as xerostomia or oral infections are common in palliative care patients and can significantly impair quality of life. Adequate dental care may contribute substantially to symptom control and well-being; however, oral health and dental services are often insufficiently integrated into palliative care practice. In addition, little is known about the level of awareness, knowledge, and interprofessional collaboration regarding oral health among palliative care professionals.\n\nThis prospective, non-interventional survey study aims to assess the relevance of oral health in palliative care by surveying both palliative care patients and healthcare professionals who are members of the German Society for Palliative Medicine. The study investigates patients' oral health status, oral health-related quality of life, and access to dental care, as well as professionals' knowledge, attitudes, and current practices related to oral health and dental care in palliative settings. The findings are intended to identify existing gaps and inform strategies for improved integration of dental expertise into palliative care.",[639,640,30,641],"Oral Health Care","Oral Health-Related Quality of Life","Palliative Care, Patient Care","2026-02-24",{"date":644,"type":39},"2026-02-27",{"date":642,"type":39},{"date":647,"type":22},"2026-06",{"name":649,"class":82},"University Medical Center Goettingen",{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":4,"eligibilityCriteria":656,"healthyVolunteers":296,"sex":17,"minAge":18,"maxAge":657,"enrollmentInfo":658,"targetDuration":4,"studyType":537,"phases":4,"briefSummary":660,"conditions":661,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":663,"lastUpdatePostDateStruct":664,"startDateStruct":666,"completionDateStruct":667,"leadSponsor":669,"locationsCount":4},"100625816","palliative-care-and-the-terminally-ill-adults-end-of-life-bill-100625816","NCT07427550","Palliative Care and The Terminally Ill Adults (End of Life) Bill","The Potential Impact of the Terminally Ill Adults (End of Life) Bill on the Professional Identity of Palliative Care Staff","Inclusion Criteria:\n\n* Palliative care staff, including Palliative nurses, Doctors and Consultants.\n* Registered with the appropriate professional registration body\n* Must have been in qualified position and working in palliative care for at least 6 months\n* Must have worked with palliative patients in the last three months\n* Fluency in English\n\nExclusion Criteria:\n\n* No direct contact with patients\n* Must be in a directly caring role within the team (does not include administrative or housekeeping staff).","80 Years",{"count":659,"type":22},6,"The current study aims to investigate the potential impact of the proposed Assisted Dying (Terminally Ill Adults (2024) Bill on Palliative care workers. Palliative care professionals across the Humber Health Partnership will be interviewed using semi-structured interview questions, with the intention of exploring the way they make sense of the potential implementation of the bill, particularly in relation to their professional identity. The research will be carried out in line with guidance for Interpretative Phenomenological Analysis (Smith, Flowers \\& Larkin, 2021), a research methodology which aims to explore how people make sense of their experience, often in response to a particular event.\n\nIt is hoped that the study will contribute to the ongoing discussions regarding how the bill should be implemented and offer potential insights into ways that hospitals may best support staff during the passing of the bill into law. The study will be sponsored by Hull University Teaching Hospitals Trust (HUTH).",[662,30],"Assisted Dying","2026-02-16",{"date":665,"type":39},"2026-02-23",{"date":623,"type":22},{"date":668,"type":22},"2027-05-01",{"name":670,"class":466},"Hull University Teaching Hospitals NHS Trust"]